Oculis Q2 2026 Results: Finance Gains Narrow the Net Loss

Oculis (Nasdaq: OCS) reported Q2 2026 grant income of CHF0.31 million, up from CHF0.26 million a year earlier, while basic and diluted loss per share narrowed to CHF0.16 from CHF0.49. The quarterly net loss fell to CHF9.97 million from CHF25.38 million, although the operating loss widened as expenses increased. Cash, cash equivalents and short-term investments totaled CHF228.3 million ($282.3 million) at June 30, supporting the company’s stated runway into the second half of 2029.

Core financial results

Oculis did not report product revenue, with operating income consisting of grant income. Research and development expenses increased modestly, while general and administrative expenses rose by about 40%, producing a wider operating loss. The company attributed the increase in operating expenses primarily to headcount-related costs, including share-based compensation, incurred to execute its development strategy.

The reported net loss nevertheless narrowed substantially because the finance result swung from a loss to a gain. This improvement came primarily from the revaluation of warrant liabilities and favorable foreign-currency movements rather than lower operating costs.

Business and pipeline performance

Oculis continued its strategic pivot toward neuro-ophthalmology, positioning Privosegtor as its lead late-stage asset. Licaminlimab remains the other core clinical program, while the company has decided not to pursue an FDA filing for OCS-01 in diabetic macular edema following the DIAMOND topline results.

The principal development updates and upcoming milestones are concentrated in the following programs:

PIONEER-1 is evaluating Privosegtor in optic neuritis patients with and without multiple sclerosis. Under a Special Protocol Assessment agreement with the FDA, the primary endpoint is the proportion of patients achieving at least a 15-letter improvement in low-contrast visual acuity at Month 3. Patients will be followed through Month 12 for long-term safety and tolerability.

For acute MS relapses, the FDA supported a development approach that could include patients with optic neuritis and other relapses. The agency’s feedback also supported a primary endpoint as early as three months and the same 3 mg/kg dose administered daily for five days as in PIONEER-1.

PREDICT-1 plans to enroll approximately 160 patients, about two-thirds of whom are expected to have the specified TNFR1 genotype. Its primary endpoint measures the change in global ocular discomfort severity through Day 29 in the genotype-defined population. Oculis acknowledged that dry-eye symptom measurements are inherently subjective, with the genotype-based design intended to identify patients more likely to respond.

Finance gains masked a wider operating loss

Oculis’ quarterly operating loss widened by CHF2.8 million, but its net loss improved by approximately CHF15.4 million. The difference was driven by an CHF18.2 million positive swing in the finance result, rather than an improvement in the underlying cost base.

The company recorded a CHF12.1 million gain from the fair-value adjustment of warrant liabilities, compared with a CHF0.2 million loss a year earlier. It also reported a CHF1.2 million foreign-exchange gain, reversing a CHF4.7 million loss in Q2 2025. These items more than offset the higher R&D and administrative spending, but they can vary with warrant valuations and currency movements.

Cash runway and balance sheet

Cash, cash equivalents and short-term investments increased to CHF228.3 million at June 30, 2026, from CHF213.0 million at December 31, 2025. In U.S. dollar terms, the total rose to $282.3 million from $268.7 million. Oculis said the increase reflected year-to-date proceeds from ordinary-share sales under its existing at-the-market offering program, partially offset by operating expenses.

Within the total, cash and cash equivalents declined to CHF61.6 million from CHF81.3 million, while short-term financial assets increased to CHF166.7 million from CHF131.7 million. Management expects the combined liquidity position to fund operations into the second half of 2029.

Risks investors need to watch

• Clinical execution remains central. PIONEER-1 is still progressing through global site activation, and Oculis is building a network connecting emergency physicians, ophthalmologists and neurologists to identify and treat eligible patients.
• PREDICT-1 depends on a genotype-defined population and a subjective symptom measure. Trial results will need to demonstrate whether this precision-medicine approach produces a clear treatment effect in the specified TNFR1 subgroup.
• The lower net loss did not reflect improved operating profitability. Operating expenses and the operating loss increased, while favorable warrant-liability and currency adjustments drove the reported improvement.
• The pipeline has become more concentrated. Oculis does not currently plan to seek FDA approval for OCS-01 in diabetic macular edema, leaving Privosegtor and Licaminlimab as its two core development candidates.
• Equity financing affects the capital structure. The higher liquidity balance partly resulted from ordinary shares sold through the at-the-market program, while clinical development continues to require substantial spending.

Summary

Oculis’ Q2 2026 net loss narrowed sharply, but the improvement came from warrant-liability and foreign-exchange gains as the operating loss widened. The company’s CHF228.3 million liquidity position provides runway into the second half of 2029, giving it resources to advance PIONEER-1, prepare the acute MS relapse IND and complete PREDICT-1. The next major operating tests are continued Privosegtor trial execution and Licaminlimab topline results around year-end.